East Windsor, N.J. (July 6, 2016) – Sabinsa Corp. has filed lawsuits in the United States District Court, District of New Jersey, against four dietary supplement ingredient companies for making, selling, and/or importing products that infringe upon Sabinsa’s Tetrahydrocurcuminoid Patent covering compositions and methods of using tetrahydrocurcuminoids in the US. The companies are: Olive Lifesciences Pvt. Ltd. (Bangalore, India), Nachurel Ingredients LLC (North Brunswick, NJ), Chemill Inc. (Bothell, WA), and Aegle Bios Inc. (Edison, NJ). Both Olive and Nachurel were named in a previous suit for infringement on another of Sabinsa’s patents.

The issued U.S. Patent No. 6,653,327, on the compositions and uses of tumericderived tetrahydrocurcuminoids is public knowledge, as is Sabinsa’s stated intent to protect the company’s intellectual property.

“We are determined to protect our intellectual property when our patents are infringed upon. These defendants’ customers are also infringing upon Sabinsa’s patents, most likely without their knowledge, so these infringing companies are putting their customer’s businesses at risk,” said Sabinsa founder Muhammed Majeed PhD. “We have been very outspoken in calling on industry manufacturers to respect intellectual property; to do otherwise both stifles innovation and does a disservice to those manufacturers who legitimately license intellectual property.”

“We are determined to protect our intellectual property when our patents are infringed upon. These defendants’ customers are also infringing upon Sabinsa’s patents, most likely without their knowledge, so these infringing companies are putting their customer’s businesses at risk,” said Sabinsa founder Muhammed Majeed PhD. “We have been very outspoken in calling on industry manufacturers to respect intellectual property; to do otherwise both stifles innovation and does a disservice to those manufacturers who legitimately license intellectual property.”

“Sabinsa's patent claims compositions and methods of using its tetrahydrocurcuminoid compositions” stated James H. Hulme, Esquire of Arent Fox LLP in Washington, DC, who represents Sabinsa in this matter. “Sabinsa will enforce its patent rights and protect its intellectual property to the fullest extent allowed by law,” he explained.

Sabinsa’s patent covers compositional claims and also several topical and oral applications of tetrahydrocurcuminoids noted for their high antioxidant capacity.

About Sabinsa Corporation:

Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and wellbeing. Over the past 20 years, Sabinsa has brought to market more than 100 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 full time scientists conducting ongoing research in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. Most of our products intended for human consumption are certified Kosher, with many certified Halal.For more information, visit www.sabinsacosmetics.com